Rina-S (rinatabart sesutecan) - Genmab
Rina-S: "Encouraging confirmed ORR, including deep responses, observed with Rina-S 120 mg/m2"; Ovarian cancer (Genmab A/S) - May 9, 2025 - Q1 2025 Results 
P1/2 data • Oncology • Ovarian Cancer
https://ir.genmab.com/static-files/4eb667d6-6c47-4e11-ab4a-72c83cf8fd79
 
May 9, 2025
 
 
8c3834a0-386b-4fe6-9c40-306d9370a14e.png